Publications 2021 Archivi

IRBM & Heidelberg University Hospital publishes in Cell Reports Medicine on kynurenine pathway activation and deviation to anthranilic and kynurenic acid in fibrosing chronic Graft-Versus-Host Disease

Publications, Publications 2021

Our Biomarkers team, in collaboration with Dr. Thomas Luft group at the Heidelberg University Hospital (Germany), explored the role of tryptophan metabolites in the acute and chronic graft versus host disease (GVHD) following allogenic bone marrow transplantation. GVHD is an…

A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors

Publications, Publications 2021, Scientific Contributions

Following the first report in the Journal of Medicinal Chemistry in 2020, the IRBM peptide chemistry group is proud to announce a new publication on second generation, potent bi- and tricyclic PCSK9 inhibitor peptides in collaboration with the extraordinary drug discovery team at Merck & co.

Discovery and characterization of novel peptide inhibitors of the NRF2/MAFG/DNA ternary complex for the treatment of cancer

News, Publications, Publications 2021, Scientific Contributions

Our Peptide Chemistry team, in collaboration with scientists at Merck and Co., reported on the design, synthesis and characterization of potent and stable peptides able to inhibit the binding of NRF2-MAFG heterodimeric transcription factor to Antioxidant Response Element (ARE) DNA sequence.

Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma

News, Publications, Publications 2021

At IRBM we are passionate about helping companies develop medicines in a wide range of diseases and our scientists support the fundamental understanding of disease mechanisms. Science is about collaboration, and publication is an integral part of the scientific process.

IRBM Publish In Science Translational Medicine On Using HTT-lowering Therapies To Slow Down Neurodegeneration In Huntington’s Disease

IRBM cited in UniQure publication on using HTT-lowering therapies to slow down neurodegeneration in Huntington’s Disease

Publications, Publications 2021, Scientific Contributions

UniQure has just published a study in Science Translational Medicine using a Huntingtin (HTT)-lowering therapy. IRBM is delighted to have been able to contribute to this pivotal work and to be cited on the publication. Huntingtin is the gene that…

Identification of Potent and Long-Acting Single-Chain Peptide Mimetics of Human Relaxin-2 for Cardiovascular Diseases

Publications, Publications 2021, Scientific Contributions

Our integrated drug discovery efforts on the Relaxin-2 peptide hormone, in collaboration with our collaborators at global life sciences company Sanofi, has produced a paper just published in the Journal of Medicinal Chemistry. The natural peptide hormone human relaxin-2 has…

Cookie	Duration	Description
_ga	2 years	The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_gat_gtag_UA_35080545_1	1 minute	Set by Google to distinguish users.
_gid	1 day	Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
vuid	2 years	Vimeo installs this cookie to collect tracking information by setting a unique ID to embed videos to the website.

MEET THE TEAM